Please assess the completion status of the following clinical trial:

Trial Title: Omacetaxine and Decitabine in Acute Myelogenous Leukemia (AML) and Myelodysplastic Syndrome (MDS)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Previously untreated AML (\>/= 20% blasts) or AML M6. Patients with high-risk (intermediate-2 or high by IPSS or \>/= 10% blasts) MDS will also be eligible. Prior therapy with hydroxyurea, biological or targeted therapy (e.g. flt3 inhibitors, other kinase inhibitors, azacitidine), or hematopoietic growth factors is allowed. No prior chemotherapy is allowed except for a single or a two day dose of cytarabine (up to 3 g/m2) for emergency use is also allowed as prior therapy.~2. Age \>/= 70 years.~3. Eastern Cooperative Oncology Group (ECOG) performance status \</= 2.~4. Adequate hepatic (serum total bilirubin \</= 1.5 x ULN, serum glutamate pyruvate transaminase (SGPT) and/or SGOT \</= 2.5 x ULN) and renal function (creatinine \</= 2.0 mg/dL).~5. Patients must be willing and able to review, understand, and provide written consent before starting therapy.~6. Men of childbearing potential who agree to use contraception prior to study entry and for the duration of participation.~Exclusion Criteria:~1. New York Heart Association (NYHA) class III or IV heart disease, active ischemia or any other uncontrolled cardiac condition such as angina pectoris, clinically significant cardiac arrhythmia and requiring therapy, uncontrolled hypertension (blood pressure \>/= 160 systolic and \>/= 110 diastolic not responsive to antihypertensive medication), uncontrolled diabetes mellitus, or congestive heart failure.~2. Myocardial infarction in the previous 12 weeks (from the start of treatment).~3. Active and uncontrolled disease/infection as judged by the treating physician.~4. Acute promyelocytic leukemia (APL).

- Gender: ALL
- Minimum Age: 70 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Omacetaxine + Decitabine (Type: EXPERIMENTAL): Phase I and Phase II Omacetaxine Dose: 1.25 mg/m2 subcutaneously every 12 hours on Days 1 - 3 of a 28 day cycle.~Phase I Starting Decitabine Dose: 20 mg/m2 by vein on Days 1 - 5 of a 28 day cycle.~Phase II Starting Decitabine Dose: Maximum tolerated dose from Phase I.

Based on this trial design, predict the completion outcome and termination type (if applicable).